GILENYA (fingolimod) Patient Assistance Program
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Gilenya (fingolimod) is FDA-approved for relapsing forms of multiple sclerosis (MS) — including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS — in patients ≥10 years. It is a sphingosine-1-phosphate (S1P) receptor modulator.
- Without assistance, brand Gilenya costs commonly run approximately $8,500–$10,500 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Gilenya for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- Generic fingolimod is now widely available in the U.S. at substantially lower cost — often $200–$600/month with a coupon. Other S1P modulators include siponimod (Mayzent), ozanimod (Zeposia), and ponesimod (Ponvory). For relapsing MS, multiple disease-modifying therapy options exist across mechanisms.
What Is Gilenya Prescription Assistance Program?
The Gilenya Prescription Assistance Program is a manufacturer-sponsored initiative that provides Gilenya at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for relapsing MS patients who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, neurology coordination, baseline screening documentation, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, brand Gilenya costs roughly $8,500–$10,500/month. Generic fingolimod is dramatically cheaper. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$10,200 | Save ~$10,130/mo |
| CVS Pharmacy (brand) | ~$10,500 | Save ~$10,430/mo |
| Walmart (brand) | ~$8,800 | Save ~$8,730/mo |
| Costco (brand) | ~$8,600 | Save ~$8,530/mo |
Generic fingolimod | $400 | Already low |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Gilenya Prescription Program?
The Patient Assistance Program is free to apply for and provides Gilenya at no medication cost if approved. Our $69.95/month service covers full advocacy. With generic fingolimod widely available at much lower cost, generic is usually the most affordable path for most patients.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Gilenya:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $8,500–$10,500 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Gilenya assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Gilenya Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Gilenya:
Gilenya (fingolimod) is a once-daily oral sphingosine-1-phosphate (S1P) receptor modulator used to treat relapsing forms of multiple sclerosis. By trapping autoreactive lymphocytes in lymph nodes, fingolimod reduces immune attack on the central nervous system.
How Gilenya Works:
Multiple sclerosis is driven by autoreactive T-cells and B-cells migrating into the central nervous system to attack myelin and axons. Fingolimod works by being phosphorylated into an active form that binds to sphingosine-1-phosphate (S1P) receptors on these lymphocytes, triggering receptor internalization. Without functional S1P receptors, lymphocytes are effectively “trapped” inside lymphoid tissues and cannot exit to migrate to the CNS. This mechanism causes a 70–80% drop in circulating lymphocyte counts within weeks, leading to a reduced relapse rate, decreased MRI lesion activity, and slowed disability progression.
Form and use:
Gilenya is administered orally as a once-daily capsule taken with or without food, with a standard adult dose of 0.5 mg and weight-based pediatric dosing for patients aged 10 and older. Due to cardiac risks, a first-dose observation (FDO) is strictly required, which involves 6 hours of continuous cardiac monitoring after the initial dose to check for bradycardia. Before initiating treatment, patients must undergo an extensive baseline screening process. This screening includes an electrocardiogram (ECG), an ophthalmologic exam, a varicella titer, a complete blood count (CBC), and liver function tests (LFTs).
Generic availability:
Generic fingolimod is widely available in the United States at a substantially lower cost than the brand-name drug Gilenya. Patients also have access to other specialized S1P modulators, such as siponimod (for active secondary progressive MS), ozanimod, and ponesimod. Furthermore, the broader landscape of multiple sclerosis disease-modifying therapies (DMTs) includes generic options like glatiramer acetate, dimethyl fumarate, and teriflunomide. A variety of other advanced treatments, ranging from interferons to monoclonal antibodies like natalizumab and ocrelizumab, are also available depending on the patient’s specific clinical needs.
Warnings:
Gilenya carries prominent warnings for bradyarrhythmia and atrioventricular (AV) block, necessitating strict first-dose cardiac observation. It also increases the risk of serious infections, including herpes, cryptococcal meningitis, and progressive multifocal leukoencephalopathy (PML), alongside risks of macular edema and hepatotoxicity. Patients may experience decreased respiratory function, elevated blood pressure, basal cell carcinoma, posterior reversible encephalopathy syndrome (PRES), or tumefactive MS lesions. Finally, the drug can cause fetal harm, requiring effective contraception during and for 2 months after treatment, and discontinuing it can trigger a severe rebound flare of MS disease activity.
FAQ (Frequently Asked Questions)
How Much Does Gilenya Cost Without Insurance?
Brand Gilenya costs approximately $8,500–$10,500 per 30-day supply. Generic fingolimod is dramatically cheaper, often $200–$600/month with a coupon. Through AffordMyPrescriptions, qualifying patients receive Gilenya at no medication cost — our $69.95 monthly fee covers full advocacy and program management. Most patients find generic fingolimod is the cheaper path.
Is Generic Fingolimod The Same As Brand Gilenya?
Yes. The FDA requires generics to be bioequivalent to brand. Generic fingolimod has the same active ingredient at the same dose as Gilenya. Most insurance plans and neurologists are comfortable using generic fingolimod for MS.
Why Do I Need First-Dose Observation?
Fingolimod can cause bradycardia (slowed heart rate) and rarely AV conduction block, especially with the first dose. Six hours of continuous cardiac monitoring after the first dose is required to detect any significant bradycardia or AV block. Observation includes baseline and post-dose ECG. The observation requirement applies to the first dose, doses restarted after >14 days off, or other specified scenarios.
What Baseline Tests Do I Need Before Starting?
Before starting fingolimod, you’ll need a recent ECG, ophthalmologic exam (to detect macular edema), varicella titer (consider varicella vaccination if seronegative — wait 4 weeks after live vaccine before starting), CBC, LFTs, and pregnancy test for those of childbearing potential. Periodic follow-up exams (eye, LFTs, BP, CBC) are needed during therapy.
Can I Stop Gilenya Suddenly?
Be very careful — severe MS rebound activity (worse than pre-treatment) has been reported after discontinuation, especially with prolonged interruption. If discontinuation is being considered, it should be done with close neurology supervision and often with transition to another DMT to bridge the lymphocyte recovery period.
How Is Gilenya Different From Newer S1P Modulators?
Newer S1P modulators (siponimod, ozanimod, ponesimod) are more selective — primarily targeting S1P1 and S1P5 — which may translate to fewer cardiac effects, less need for first-dose observation, and shorter washout periods. Gilenya remains first-line for many patients but the newer agents may be preferred in selected situations.
What If My Application Is Denied?
If denied, we explore alternatives — switching to generic fingolimod (much cheaper), or to another MS DMT with its own PAP (oral options include generic dimethyl fumarate, generic teriflunomide; infusion/injection options include glatiramer, interferons, ocrelizumab, ofatumumab), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the National MS Society, MS Association of America, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Gilenya, our team may be able to help you access assistance programs — or guide you to generic fingolimod if it fits your situation. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.